prosthesis
发表于 2025-3-27 00:52:54
http://reply.papertrans.cn/87/8670/866972/866972_31.png
预测
发表于 2025-3-27 04:26:59
Neurological Manifestations of Sickle Cell Disease and Their Impact on Allogeneic Hematopoietic Stemith SCA and the impact of pre-existing neurological conditions on HSCT complications and outcomes. We identify knowledge gaps and highlight recent developments. We also suggest a standardized clinical approach for assessing neurological complications of SCA before, during, and after HSCT.
自负的人
发表于 2025-3-27 08:29:08
Overview of Hematopoietic Stem Cell Transplantation for Nonmalignant Diseaseslism, and aplastic anemia and bone marrow failure syndromes. Furthermore, it touches on recent developments in reduced intensity conditioning regimens, GVHD prophylaxis, and the management of post-transplant infection risks.
财产
发表于 2025-3-27 12:19:10
http://reply.papertrans.cn/87/8670/866972/866972_34.png
过去分词
发表于 2025-3-27 15:47:40
http://reply.papertrans.cn/87/8670/866972/866972_35.png
degradation
发表于 2025-3-27 19:08:40
Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Diseaseransplant conditioning regimen have led to promising results from ongoing clinical trials. Ultimately, innovative approaches such as cell therapies may be needed to make haploidentical transplantation a safe and effective curative option for sickle cell disease.
空中
发表于 2025-3-27 23:00:41
http://reply.papertrans.cn/87/8670/866972/866972_37.png
CANE
发表于 2025-3-28 05:09:58
http://reply.papertrans.cn/87/8670/866972/866972_38.png
枪支
发表于 2025-3-28 07:06:27
http://reply.papertrans.cn/87/8670/866972/866972_39.png
Myelin
发表于 2025-3-28 10:57:29
Current Non-HSCT Treatments for SCDth care and public policies have successfully reduced the mortality in children with SCD and has led to its evolution into a chronic disease in adults living with SCD. While management of SCD remains largely symptomatic with only one FDA-approved pharmacologic disease-modifying agent hydroxyurea, im